Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial



Fleischmann, Roy, Mysler, Eduardo, Hall, Stephen, Kivitz, Alan J, Moots, Robert J ORCID: 0000-0001-7019-6211, Luo, Zhen, DeMasi, Ryan, Soma, Koshika, Zhang, Richard, Takiya, Liza
et al (show 6 more authors) (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. LANCET, 390 (10093). 457 - 468.

[img] Text
1187 manuscript_response to Lancet comments_22 May 17_CLEAN.DOCX - Accepted Version

Download (722kB)

Abstract

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate response to methotrexate.

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 29 Jun 2017 09:59
Last Modified: 15 Sep 2022 20:11
DOI: 10.1016/S0140-6736(17)31618-5
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3008189